YC-1
SIGMA/Y102 - powder
Synonym: 3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole
CAS Number: 170632-47-0
Empirical Formula (Hill Notation): C19H16N2O2
Molecular Weight: 304.34
MDL Number: MFCD06407798
Linear Formula: C19H16N2O2
Product Type: Chemical
| color | white to yellow |
| form | powder |
| InChI | 1S/C19H16N2O2/c22-13-15-1 |
| InChI key | OQQVFCKUDYMWGV-UHFFFAOYSA |
| Quality Level | 200  |
| SMILES string | OCc1ccc(o1)-c2nn(Cc3ccccc |
| solubility | DMSO: 10 mg/mL |
| H2O: insoluble |
| Application: | YC-1 has been used as a hypoxia-inducible factor 1α (HIF-1α) inhibitor: • to reduce hypoxia induced Jagged1 expression in cardiomyocytes (CMs) • to study its effect on progenitor expansion and CD34+ and side population (SP) cell phenotype and on the proliferation rate of cells with an ability to form long term colony forming units • to study its effect on regulating sphingosine 1-phosphate (S1P) bound to albumin induced plasminogen activator inhibitor 1 (PAI-1) expression by activating Rho/ Rho-associated protein kinase (ROCK) pathway. |
| Biochem/physiol Actions: | NO (nitric oxide)-independent activator of soluble guanylyl cyclase. |
| Biochem/physiol Actions: | YC-1 activates soluble guanylyl cyclase and prevents platelet aggregation and vascular contraction. It has a potential to treat circulation disorders. YC-1 also has an ability to inhibit hypoxia-inducible factor 1α (HIF-1α) activity in vitro. It acts as a potential antiangiogenic anticancer agent. |
| Features and Benefits: | This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Packaging: | 25 mg in glass insert |
| Packaging: | 5 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| UNSPSC | 41106305 |